+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Migraine Drugs Market by Drug Class (Cgrp Monoclonal Antibodies, Ditans, Ergot Derivatives), Route Of Administration (Injectable, Nasal, Oral), Distribution Channel, Indication, Patient Age Group - Global Forecast 2025-2030- Product Image
Migraine Drugs Market by Drug Class (Cgrp Monoclonal Antibodies, Ditans, Ergot Derivatives), Route Of Administration (Injectable, Nasal, Oral), Distribution Channel, Indication, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

Migraine Drugs Market by Drug Class (Cgrp Monoclonal Antibodies, Ditans, Ergot Derivatives), Route Of Administration (Injectable, Nasal, Oral), Distribution Channel, Indication, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968814
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The migraine drugs market continues to transform as advanced therapies and digital technologies redefine migraine management and patient outcomes. Strategic leaders require an integrated perspective on commercial opportunities, evolving treatment modalities, and regulatory pressures shaping market dynamics.

Market Snapshot: Migraine Drugs Market Growth Trajectory

The migraine drugs market grew from USD 5.48 billion in 2024 to USD 6.39 billion in 2025. It is expected to continue growing at a CAGR of 15.88%, reaching USD 13.28 billion by 2030. This sector is propelled by rising patient awareness, a steady pipeline of novel therapies, and strengthened demand for both acute and preventive treatments. Stakeholders are competing in a landscape where product innovation, access, and cost challenges converge, underscoring the need for informed, evidence-based decisions.

Scope & Segmentation of the Migraine Drugs Market

  • Drug Class: CGRP monoclonal antibodies (eptinezumab, erenumab, fremanezumab, galcanezumab), Ditans (lasmiditan), Ergot derivatives (dihydroergotamine, ergotamine), Gepants (atogepant, rimegepant, ubrogepant), NSAIDs (diclofenac, ibuprofen, naproxen), Triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan)
  • Route of Administration: Injectable (intravenous, subcutaneous), nasal, oral (capsules, tablets), topical, transdermal
  • Distribution Channel: Offline, online
  • Indication: Acute treatment, preventive treatment
  • Patient Age Group: Adult, Pediatric (adolescents, children, neonates)
  • Region: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies: AbbVie Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, H. Lundbeck A/S, Biohaven Pharmaceutical Holding Company Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc

Key Takeaways for Senior Decision-Makers

  • The transition from conventional analgesics to targeted therapies has led to new treatment protocols and impacted patient satisfaction trends.
  • Monoclonal antibodies, gepants, and ditans are reshaping efficacy benchmarks, with precise mechanisms of action that cater to diverse patient subgroups.
  • The continued expansion of digital health solutions, including telemedicine and remote monitoring, has enhanced both access and real-time management for migraine patients.
  • Regional adoption rates differ due to disparities in healthcare infrastructure, reimbursement standards, and clinical awareness, requiring nuanced market strategies.
  • Collaborative alliances between big pharma and emerging biotech are accelerating late-stage clinical programs and expanding supply resilience in complex environments.
  • Emphasis on pediatric and adolescent therapeutic development addresses a previously underserved patient population, driving demand for tailored dosing and long-term safety validation.

Tariff Impact: Navigating U.S. Pharmaceutical Supply Chain Uncertainties

The implementation of tariffs on pharmaceutical imports into the U.S. in 2025 is increasing production costs and compelling firms to reconsider manufacturing locations and supplier relationships. As manufacturers adapt sourcing strategies and renegotiate contracts, new collaborations with domestic organizations are emerging to protect supply continuity. These dynamics impact cost structures and patient access, with implications across pricing and reimbursement models throughout the migraine drugs market.

Methodology & Data Sources

This analysis utilizes both primary and secondary research, including expert interviews with neurologists and industry stakeholders, thorough reviews of regulatory filings and clinical trials, and comprehensive examination of industry reports, databases, and patent documents. Triangulation and quantitative modeling strengthen reliability, while scenario planning workshops stress-test findings.

Why This Report Matters

  • Gain a 360-degree understanding of the competitive landscape, including technology innovations and key company positioning across leading markets.
  • Anticipate the effects of regulatory shifts, reimbursement changes, and emerging therapies that are shaping future commercial strategies in migraine therapeutics.
  • Identify actionable growth opportunities and operational risks tailored to evolving patient segments and geographic markets.

Conclusion

Leaders who adopt integrated approaches, embrace partnership-driven innovation, and respond proactively to regulatory and economic shifts will be best positioned to drive long-term success. This report offers essential strategic insights for navigating the fast-evolving migraine therapeutics landscape with confidence.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid payer adoption and reimbursement challenges for CGRP monoclonal antibody therapies in migraine treatment
5.2. Growing market penetration of gepant oral CGRP receptor antagonists for acute migraine relief and prevention
5.3. Surge in real-world evidence generation influencing payer coverage and formulary decisions for novel migraine drugs
5.4. Introduction of fast-acting 5HT1F receptor agonists offering alternative acute migraine relief for triptan nonresponders
5.5. Integration of digital therapeutics and wearable monitoring platforms into personalized chronic migraine management plans
5.6. Advancements in noninvasive neurostimulation devices expanding nonpharmacological options for refractory migraine sufferers
5.7. Development of biosimilar versions of high-cost migraine biologics poised to disrupt pricing and market competition
5.8. Implementation of value-based contracting and outcomes-based agreements for high-cost migraine therapies with payers
5.9. Focus on health equity initiatives to improve access and affordability of advanced migraine treatments in underserved populations
5.10. Expansion of telemedicine platforms accelerating virtual diagnosis, remote management, and patient support in migraine care
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Migraine Drugs Market, by Drug Class
8.1. Introduction
8.2. Cgrp Monoclonal Antibodies
8.2.1. Eptinezumab
8.2.2. Erenumab
8.2.3. Fremanezumab
8.2.4. Galcanezumab
8.3. Ditans
8.3.1. Lasmiditan
8.4. Ergot Derivatives
8.4.1. Dihydroergotamine
8.4.2. Ergotamine
8.5. Gepants
8.5.1. Atogepant
8.5.2. Rimegepant
8.5.3. Ubrogepant
8.6. Nsaids
8.6.1. Diclofenac
8.6.2. Ibuprofen
8.6.3. Naproxen
8.7. Triptans
8.7.1. Almotriptan
8.7.2. Eletriptan
8.7.3. Frovatriptan
8.7.4. Naratriptan
8.7.5. Rizatriptan
8.7.6. Sumatriptan
8.7.7. Zolmitriptan
9. Migraine Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.2.2. Subcutaneous
9.3. Nasal
9.4. Oral
9.4.1. Capsule
9.4.2. Tablet
9.5. Topical
9.6. Transdermal
10. Migraine Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Migraine Drugs Market, by Indication
11.1. Introduction
11.2. Acute Treatment
11.3. Preventive Treatment
12. Migraine Drugs Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Pediatric
12.3.1. Adolescents
12.3.2. Children
12.3.3. Neonates
13. Americas Migraine Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Migraine Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Migraine Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Amgen Inc.
16.3.3. Novartis AG
16.3.4. Eli Lilly and Company
16.3.5. H. Lundbeck A/S
16.3.6. Biohaven Pharmaceutical Holding Company Ltd.
16.3.7. Teva Pharmaceutical Industries Ltd.
16.3.8. Pfizer Inc.
16.3.9. Merck & Co., Inc.
16.3.10. GlaxoSmithKline plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MIGRAINE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. MIGRAINE DRUGS MARKET: RESEARCHAI
FIGURE 26. MIGRAINE DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. MIGRAINE DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. MIGRAINE DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MIGRAINE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 185. CANADA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. CANADA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. CANADA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 188. CANADA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 189. CANADA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
TABLE 190. CANADA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2030 (USD MILLION)
TABLE 191. CANADA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 192. CANADA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 193. CANADA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
TABLE 194. CANADA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2030 (USD MILLION)
TABLE 195. CANADA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 196. CANADA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 197. CANADA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 198. CANADA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 199. CANADA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. CANADA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. CANADA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 202. CANADA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 203. CANADA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 204. CANADA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 205. CANADA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. CANADA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. CANADA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. CANADA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. CANADA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. CANADA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. CANADA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 212. CANADA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 213. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 214. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 215. MEXICO MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 216. MEXICO MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 217. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
TABLE 218. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2030 (USD MILLION)
TABLE 219. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 220. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 221. MEXICO MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
TABLE 222. MEXICO MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2030 (USD MILLION)
TABLE 223. MEXICO MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 224. MEXICO MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 225. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 226. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 227. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. MEXICO MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 230. MEXICO MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 231. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 232. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 233. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. MEXICO MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. MEXICO MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 238. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 239. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 240. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 320. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 321. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 322. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 323. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 324. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 325. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 326. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 327. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 328. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 329. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 330. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 331. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
TABLE 332. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2030 (USD MILLION)
TABLE 333. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 334. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 335. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
TABLE 336. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2030 (USD MILLION)
TABLE 337. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 338. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 339. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 340. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 341. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 342. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 343. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 344. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 345. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 346. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 347. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 348. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 349. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 350. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 351. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 352. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 353. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 354. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 355. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 3

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.28 Billion
Compound Annual Growth Rate15.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Migraine Drugs Market Size, Share & Trends Analysis Report by Treatment (Acute, Preventive), Therapeutic Class, Route of Administration, Age Group (Pediatric, Adult, Geriatric), Availability, Region, with Growth Forecasts, 2025-2030 - Product Image

Migraine Drugs Market Size, Share & Trends Analysis Report by Treatment (Acute, Preventive), Therapeutic Class, Route of Administration, Age Group (Pediatric, Adult, Geriatric), Availability, Region, with Growth Forecasts, 2025-2030

  • Report
  • 159 Pages
  • Global
From
Migraine Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Migraine Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 95 Pages
  • Global
From
Migraine Drugs - Global Strategic Business Report - Product Image

Migraine Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Acute Migraine Treatment Market Report 2025 - Product Image

Acute Migraine Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Migraine Drug Market

The Migraine Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Migraine drugs are used to treat the symptoms of migraine headaches, such as nausea, vomiting, and sensitivity to light and sound. These drugs can be divided into two categories: abortive and preventive. Abortive drugs are taken at the onset of a migraine attack to reduce the severity of symptoms, while preventive drugs are taken on a regular basis to reduce the frequency of migraine attacks. Common abortive drugs include triptans, ergot alkaloids, and non-steroidal anti-inflammatory drugs (NSAIDs). Common preventive drugs include beta-blockers, anticonvulsants, and serotonin receptor agonists. Some companies in the Migraine Drug market include GlaxoSmithKline, Pfizer, Novartis, Merck, and Allergan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.